Methods: We analyzed COVID-19 surveillance data from January to July 2023 across 33 California state prisons, primarily a male population of 96,201 individuals. We computed the incidence rate of new COVID-19 infections among COVID-bivalent-vaccinated and entirely unvaccinated groups (those not having received either the bivalent or monovalent vaccine).
Results: Our results indicate that the infection rates in the bivalent-vaccinated and entirely unvaccinated groups are 3.24% (95% confidence interval (CI): 3.06-3.42%) and 2.72% (CI: 2.50-2.94%), respectively, with an absolute risk difference of only 0.52%. When the data were filtered for those aged 50 and above, the infection rates were 4.07% (CI: 3.77-4.37%) and 3.1% (CI: 2.46-3.74%), respectively, revealing a mere 0.97% absolute risk difference. Among those aged 65 and above, the infection rates were 6.45% (CI: 5.74-7.16%) and 4.5% (CI: 2.57-6.43%), respectively, with an absolute risk difference of 1.95%.
Conclusions: The COVID-bivalent vaccinated group showed a higher infection rate than the unvaccinated group in the statewide category and the age ≥50 years category. However, the absolute difference in infection rates is negligible. In the older age group (≥65 years), there was no significant difference in infection rates between the two groups. However, the unvaccinated population in this group was notably smaller and likely not sufficiently powered.
Younger age groups are less likely to have had the spring 2022 booster unless they were in a clinically high-risk category eligible for vaccination. This may explain why the hospitalisation rates were possibly slightly more elevated at a shorter interval since vaccination compared to longer intervals in these age groups: the clinical risk factors that make younger adults eligible for Spring 2022 vaccination may also make them more pre-disposed to hospital admissions than the general age matched population. For example, patients with immunosuppression, in whom the vaccines may also be less effective.
Experimental design: Mass spectrometry examination of biological samples was used to detect the presence of specific fragments of recombinant Spike protein in subjects who received mRNA-based vaccines.
Results: The specific PP-Spike fragment was found in 50% of the biological samples analyzed, and its presence was independent of the SARS-CoV-2 IgG antibody titer. The minimum and maximum time at which PP-Spike was detected after vaccination was 69 and 187 days, respectively.
Schematic diagram of PP Spike protein production. (A) Formation of Spike PP protein after injection of vaccine mRNA. (B) Example of wild-type, unmodified Spike protein. (C) Extraction and detection scheme (more details in the text). (D) quantification of the antibody titer of the 20 vaccinated cases. (E) Time from the day of vaccination completion to the discovery of vaccine mRNA-induced Spike protein “PP”.
Results COVID-19 occurred in 1475 (3%) of 48 344 employees during the 100-day study period. The cumulative incidence of COVID-19 was lower in the “not up-to-date” than in the “up-to-date” state. On multivariable analysis, not being “up-to-date” with COVID-19 vaccination was associated with lower risk of COVID-19 (HR, 0.77; 95% C.I., 0.69-0.86; P-value, <0.001). Results were very similar when those 65 years and older were only considered “up-to-date” after receiving 2 doses of the bivalent vaccine.
Conclusions Since the XBB lineages became dominant, adults “not up-to-date” by the CDC definition have a lower risk of COVID-19 than those “up-to-date” on COVID-19 vaccination, bringing into question the value of this risk classification definition.
Summary Among 48 344 working-aged Cleveland Clinic employees, those not “up-to-date” on COVID-19 vaccination had a lower risk of COVID-19 than those “up-to-date”. The current CDC definition provides a meaningless classification of risk of COVID-19 in the adult population.
As early as June 2021 - less than six months after mRNA jabs began, less than five months after anyone could be considered fully vaccinated - a significant fraction of people hospitalized with Covid had been jabbed. The Maryland data could not be clearer. The most interesting fact is when they started to fail:
Yes, in July 2021, as the United States government told Americans that two mRNA shots provided near-total protection from Covid, more than one in five people hospitalized with Covid in Maryland was “fully vaccinated.” (In June the figure was 18 percent.)
Worse, Maryland’s 20 percent “fully vaccinated” hospitalization figure for July 2021 is a significant underestimate, since Maryland systematically misclassified vaccinated people as unvaccinated. As Maryland itself explains: “Identification of post-vaccination infections requires that vaccination data be reported to the state immunization registry and… be matched to the SARS-CoV-2 test result. Therefore, post-vaccination infections may be undercounted.”
Clinical trial data for the mRNA COVID-19 vaccines makes it unclear that they were beneficial for the most serious health outcomes. As the pandemic has progressed there should be fewer net benefits to the vaccines, meaning that they could be net harmful now, and safety signals are increasing.
In 10 of 108 HCV patient samples, full-length or traces of SARS-CoV-2 spike mRNA vaccine sequences were found in blood up to 28 days after COVID-19 vaccination. Detection of mRNA vaccine sequences in blood after vaccination adds important knowledge regarding this technology and should lead to further research into the design of lipid-nanoparticles and the half-life of these and mRNA vaccines in humans.
We expect that vaccine mRNA detected in plasma is contained within LNPs and that the LNPs in plasma have been slowly released from the injection site either directly to the blood or through the lymph system. Without the LNPs protecting the mRNA, the mRNA would rapidly degrade. This allows prolonged spike protein production giving an advantage for a continuous immune response in some persons. Current studies on half-life of mRNA vaccines could have underestimated the half-life of the LNPs, primarily using results from half-life of studies of mRNA in the cytosol of human cells.
COVID-19 cases and deaths per week decreased faster in regions where less boosters were administered since July 1st 2021. The more booster doses were administered in a region, the longer the virus prevailed there.
…IgG4 is considered as an anti-inflammatory IgG with low potential to mediate Fc-dependent effector function such as ADCC or ADCP (20, 45).
High levels of antigen-specific IgG4 have been reported to correlate with successful allergen-specific immunotherapy by blocking IgE-mediated effects (46). In addition, increasing levels of bee venom-specific IgG4 have been detected in beekeepers over several beekeeping seasons and finally even became the dominant IgG subclass for the specific antigen, i.e. phospholipase A (PLA).
So far, only few studies on the role of vaccine-induced IgG4 responses against infectious diseases are available. In the field of HIV vaccine development, repeated protein immunization in the trial VAX003 (49) led to higher levels of HIV gp120-specific IgG2 and IgG4, whereas a prime-boost immunization with a canarypox vector (ALVAC) and the same protein vaccine in the RV144 trial (50) resulted in higher HIV-specific IgG3 responses correlating with partial protection against HIV (51, 52). Furthermore, the vaccine-elicited IgG3 antibodies enhanced effector functions as ADCC and ADCP, but vaccine-induced IgG4 inhibited those functions (52).
In our study, antibody-mediated phagocytic activity and complement deposition were reduced in sera after the third immunization, in parallel to higher proportions of anti-spike IgG4 antibodies. …our results clearly demonstrate that a subsequent infection can further boost IgG4 antibody levels, with IgG4 becoming the most dominant among all anti-spike IgG subclasses in some individuals.
The Lancet COVID-19 Commission published an article on Sept. 14, 2022 about the lessons learned from the COVID-19 pandemic. As of May 31, 2022, 6.9 million deaths from COVID-19 were reported, but the estimated excess death toll is 17.2 million, based on data from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. The report states that “this staggering death toll is both a profound tragedy and a massive global failure at multiple levels.”
Pfizer and Moderna mRNA COVID-19 vaccines were associated with an excess risk of serious adverse events of special interest of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95 % CI −0.4 to 20.6 and −3.6 to 33.8), respectively. Combined, the mRNA vaccines were associated with an excess risk of serious adverse events of special interest of 12.5 per 10,000 vaccinated (95 % CI 2.1 to 22.9); risk ratio 1.43 (95 % CI 1.07 to 1.92). The Pfizer trial exhibited a 36 % higher risk of serious adverse events in the vaccine group; risk difference 18.0 per 10,000 vaccinated (95 % CI 1.2 to 34.9); risk ratio 1.36 (95 % CI 1.02 to 1.83). The Moderna trial exhibited a 6 % higher risk of serious adverse events in the vaccine group: risk difference 7.1 per 10,000 (95 % CI –23.2 to 37.4); risk ratio 1.06 (95 % CI 0.84 to 1.33). Combined, there was a 16 % higher risk of serious adverse events in mRNA vaccine recipients: risk difference 13.2 (95 % CI −3.2 to 29.6); risk ratio 1.16 (95 % CI 0.97 to 1.39).
Newly mRNA boosted adults aged 40-74 are now TWICE as likely to be hospitalized for Covid as those who haven't recently been boosted, a new British government report shows:
The probability of reinfection increased with time from the initial infection (odds ratio of 18 months vs 3 months, 1.56; 95% CI, 1.18-2.08) (Figure) and was higher among persons who had received 2 or more doses compared with 1 dose or less of vaccine (odds ratio, 1.42; 95% CI, 1.13-1.78).
CDC’s COVID-19 prevention recommendations no longer differentiate based on a person’s vaccination status because breakthrough infections occur, though they are generally mild (16), and persons who have had COVID-19 but are not vaccinated have some degree of protection against severe illness from their previous infection (17).
The mass vaccination campaign was not justified in terms of reducing excess all-cause mortality. The large excess mortality of the covid period, far above the historic trend, was maintained throughout the entire covid period irrespective of the unprecedented vaccination campaign, and is very strongly correlated (r = +0.86) to poverty, by state; in fact, proportional to poverty. It is also correlated to several other socioeconomic and health factors, by state, but not correlated to population fractions (65+, 75+, 85+ years) of elderly state residents.
We found evidence of an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared to the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14-59 days after complete vaccination compared to ≥60 days. In contrast to vaccine-induced immunity, there was no increased risk for re-infection with Beta, Gamma or Delta variants relative to Alpha variant in individuals with infection-induced immunity.
On July 5, the RIVM - a research institute that is part of the Dutch Ministry of Health - reported a basic two-dose Covid vaccination offered no protection against Covid hospitalization. Worse, vaccinated people were 20 percent more likely to need intensive care than the unvaccinated. After seven months, vaccinated people in their fifties and sixties had a 68 percent higher risk of being hospitalized for Covid compared to the unvaccinated. They had a 41 percent higher risk of needing intensive care. The trends were similar for people 70 and over, though most of them had been boosted or received a fourth shot, so comparisons were harder to make.
Could some vaccines drive the evolution of more virulent pathogens? Conventional wisdom is that natural selection will remove highly lethal pathogens if host death greatly reduces transmission. Vaccines that keep hosts alive but still allow transmission could thus allow very virulent strains to circulate in a population. Here we show experimentally that immunization of chickens against Marek's disease virus enhances the fitness of more virulent strains, making it possible for hyperpathogenic strains to transmit. Immunity elicited by direct vaccination or by maternal vaccination prolongs host survival but does not prevent infection, viral replication or transmission, thus extending the infectious periods of strains otherwise too lethal to persist. Our data show that anti-disease vaccines that do not prevent transmission can create conditions that promote the emergence of pathogen strains that cause more severe disease in unvaccinated hosts.
A particular point of note about the with vs not-with Covid charts above is the X-axis scale:
For the deaths with Covid the mortality rate per 100,000 person-years is below 10 for all those aged under 70, and the absolute difference in mortality rate between vaccinated and unvaccinated is around 3 - 4 per 100,000 person years (albeit a bit larger for those aged over 70) — this is a low number and could be considered as being relatively unimportant.
However, the additional deaths not with Covid in the vaccine group is significant — we see over double the mortality rate for those aged under 50, and a near doubling for those aged 50-70. In this case the absolute level of the increase is frighteningly large.
“New study: COVID booster significantly delays end of infection“ (Israel National News, 2022.07.10): “31% boosted people still contagious 10 days post-infection vs. 6% unvaccinated. A new study published in the New England Journal of Medicine (NEJM) has demonstrated that people who are triple-vaccinated (boosted) against COVID recover significantly more slowly from COVID infection and remain contagious for longer than people who are not vaccinated at all. The study did not deal with the severity of illness with or without a vaccine.”
“Paxlovid Resistance emerges” (John Paul, 2022.06.30): “By analyzing genetic sequences uploaded to a public database, the authors tracked down mutations that already occurred, and are occurring, this is a useful tool and form for researchers to attempt to predict viral evolution and how the virus might adapt to treatments, therefore is an attempt to stay one step ahead of the virus. Here they found several parts of the virus which are prone to mutate because of their interactions with Nirmatrelvir, one of the two main components of Paxlovid, therefore creating drug resistance. Some of these spots were pre-existent, and continuous prescription of Paxlovid will most likely create these drug-resistant mutations, making the virus harboring them harder to treat.” In other words, Paxlovid will soon be good for nothing, if it isn’t already.
At five days post-infection, less than 25 percent of unvaccinated people were still contagious, whereas around 70 percent of boosted people were still carrying viable virus particles. For those partially vaccinated, around 50 percent were still contagious at this point.
Even more strikingly, at ten days post-infection, one-third of boosted people (31 percent) were found to still be carrying live, culturable virus. By contrast, just six percent of unvaccinated people were still contagious at day 10.
In other words, people who have received a booster shot are five times more likely still to be contagious at ten days post-infection than are unvaccinated people.
Thanks for reading Live to Fight Another Day! Subscribe for free to receive new posts and support my work.
Pfizer and Moderna mRNA COVID-19 vaccines were associated with an increased risk of serious adverse events of special interest, with an absolute risk increase of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95% CI -0.4 to 20.6 and -3.6 to 33.8), respectively.
Combined, the mRNA vaccines were associated with an absolute risk increase of serious adverse events of special interest of 12.5 per 10,000 (95% CI 2.1 to 22.9).
The excess risk of serious adverse events of special interest surpassed the risk reduction for COVID-19 hospitalization relative to the placebo group in both Pfizer and Moderna trials (2.3 and 6.4 per 10,000 participants, respectively).
“Finally Proven: Pfizer Vaccine Causes COVID Reinfections!” (Igor Chudov, 2022.06.19): “There were a total of 12 kids-participants who managed to get two COVID infections within the time frame of the trial. 11 of them were vaccine recipients and only one received no vaccine!“
A long-term study of healthcare workers in the United Kingdom has allowed their history of infection and vaccination to be traced precisely. Reynolds et al. found some unexpected immune-damping effects caused by infection with a heterologous variant to the latest wave of infection by the Omicron/Pango lineage B.1.1.529. The authors found that Omicron infection boosted immune responses to all other variants, but responses to Omicron itself were muted. Infection with the Alpha variant provided weaker boosting for Omicron-specific responses. Furthermore, Omicron infection after previous Wuhan Hu-1 infection failed to boost neutralizing antibody and T cell responses against Omicron, revealing a profound imprinting effect and explaining why frequent reinfections occur.
“Adverse effects of COVID-19 vaccines and measures to prevent them” (Virol. J., 2022.06.05): “According to European Medicines Agency recommendations, frequent COVID-19 booster shots could adversely affect the immune response and may not be feasible. The decrease in immunity can be caused by several factors such as N1-methylpseudouridine, the spike protein, lipid nanoparticles, antibody-dependent enhancement, and the original antigenic stimulus.“
“Virologic characterization of symptom rebound following nirmatrelvir-ritonavir (paxlovid) treatment for COVID-19“ (BMJ Yale, 2022.05.24): ”In summary, recurrent clinical disease after nirmatrelvir-ritonavir therapy for COVID-19 is associated with high viral load and, in some cases, culturable virus. Culturable virus was present for up to two weeks after completion of therapy. Consideration should be given to revising public health guidelines to specifically recommend repeat testing and isolation in these cases. Future work is needed to better understand the causes, clinical significance, and public health consequences of symptomatic relapse after nirmatrelvir-ritonavir.”
“Here’s What Scientists Know About Paxlovid Rebound“ (TIME, 2022.05.26):”Ho decided to study the phenomenon further when he learned that a colleague, Dr. Michael Charness at the VA Boston Healthcare System, had a similar experience. The scientists (who are both vaccinated and boosted) teamed up and conducted what is probably the most comprehensive analysis of the phenomenon to date, because they were able to conduct daily testing and track the flip from negative to positive and also perform genetic sequencing of the virus to confirm that the infection was caused by the same virus rebounding back, rather than a new infection.No antiviral drugs—whether against SARS-CoV-2 or HIV—actually kill any virus present in an infected person; they work by blocking certain steps in the virus’ replication cycle, freezing them in time so the virus cannot continue to churn out more copies of itself. Paxlovid specifically interrupts the step involving the protease enzyme, which splices the long string of polypeptides that the virus makes once it infects a cell. That lengthy protein needs to be cut into its component proteins, which then play roles in making a new virus. By inhibiting that step, Paxlovid leaves the virus in a suspended state—and depending on when the drug was started, an infected person could have thousands of these long polypeptide strings already made and floating around in the body, creating a latent reservoir of viral product that could become active again. The drug prevents these intermediary forms from getting cut and infecting cells, but once the drug stops after day 5, the enzyme is no longer inhibited and can go back to splicing and making viral proteins. That could lead to a rebound, because more virus is being made that can infect cells again.”
“Is Pfizer’s New Antiviral Drug Dangerous for the Vaccinated?“ (Darby Shaw, 2022.04.26): ”…what both Pfizer and CNN failed to note is that Pfizer excluded Covid-vaccinated patients from its clinical trial of the drug: “Inclusion/exclusion criteria specified that subjects had to have at least one of the following risk factors for progression to severe disease: ≥60 years of age; BMI >25; current smoker; immunosuppressive disease or immunosuppressive treatment; chronic lung disease; hypertension; cardiovascular disease; diabetes; chronic kidney disease; sickle cell disease; neurodevelopmental disorders; active cancer; medical related technological dependence. Individuals who had a history of prior COVID-19 infection or vaccine were excluded. [2]”
“Managing an evolving pandemic: Cryptic circulation of the Delta variant during the Omicron rise“ (Science of The Total EnvironmentVolume 836, 25 August 2022, 155599): “The resulting model predicts a significant decrease in Omicron levels within the near future, diminishing until fully disappearing (Fig. 3b). Furthermore, the Delta is also expected to decrease, but at a much lower pace, thereby still maintaining a low (yet non-vanishing) level of cryptic circulation in the population (Fig. 3b), before starting to rise again due to the waning immunity. “
“Covid-19 cases that return after antiviral treatment puzzle doctors“ (Erie News Now, 2022.04.27): “The FDA noted these rebound cases in its own analysis of the data from the clinical trials. The phenomenon was found in a small percentage of cases, roughly 10 to 14 days after starting Paxlovid. It's not clear how common these may be. A clinical trial of the medication is still ongoing. Researchers and doctors are still learning how Paxlovid works. “ Oh, really?!
“Poor N protein antibody in vaccinated“ (John Paul, 2022.04.27): “Findings Among participants in the mRNA-1273 vaccine efficacy trial with PCR-confirmed Covid-19, anti-nucleocapsid antibody seroconversion at the time of study unblinding (median 53 days post diagnosis and 149 days post enrollment) occurred in 40% of the mRNA-1273 vaccine recipients vs. 93% of the placebo recipients, a significant difference.“
“Poor virus-neutralizing capacity in highly C-19 vaccinated populations could soon lead to a fulminant spread of Sars-CoV-2 super variants that are highly infectious and highly virulent in vaccinees while being fully resistant to all existing and future spike-based C- 19 vaccines“ (G. Vanden Bossche, DVM, PhD March 2022): “As the mechanism of enhancement of infection and disease are mediated by binding of non-neutralizing Abs directed at a conserved site on the spike protein, the occurrence of ADEI and ADED will be particularly pronounced in ‘highly vaccinated- highly boosted’ populations exposed to a SC-2 variant that is largely resistant to vaccinal Abs that potentially inhibit viral infection (i.e., virus-neutralizing Abs). In the non-vaccinated, however, Omicron is boosting instead of compromising their innate immune defense against CoV, including all current and future variants. Lowering the infectious pressure in highly vaccinated populations could only be achieved by mankind conducting large scale antiviral chemoprophylaxis campaigns; if man fails to do so, there is no doubt that the virus will take care of lowering the immune pressure in these populations.“
neither of the vaccines decreased or increased the absolute risk of death by any more than 0.08% over the course of the trials.
the vaccines could prevent up to two deaths or cause up to three deaths per year among every 1,000 people.”
“Omicron a wolf in sheep's clothing” (Geert vanden Boschee, 2022. 02.17): “Given the high and steadily increasing vaccine coverage rates in large parts of the world and the ongoing mass vaccination of children and continuation of booster campaigns, I am of the opinion that Omicron has the capacity to evolve into a much less benign variant, regardless of whether or not infection prevention measures are relaxed or lifted. In contrast to the situation in vaccinated people, training of innate immune effector cells in non-vaccinated individuals initially occurs in the absence of S-specific Abs. It is, therefore, reasonable to assume that their SARS-CoV-2-experienced innate Abs can better resist competition from naturally induced non-neutralizing S-specific Abs for binding to Omicron.“
“Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination” (Hidawi, 2022.02.16): ”We report a case of a 69-year-old woman admitted to the intensive care unit due to stroke caused by thrombosis of the right carotid artery 9 days after receiving the ChAdOx1 nCov-19 vaccine. Further investigations demonstrated multiple thrombi in the arterial tree in the absence of any venous involvement.”
We found progressively waning vaccine effectiveness against SARS-CoV-2 infection of any severity across all subgroups, but the rate of waning differed according to vaccine type. With respect to severe COVID-19, vaccine effectiveness seemed to be better maintained, although some waning became evident after 4 months.
Low vaxed South Africa: 3.36 times increase in reinfection hazard; highly vaxed UK: 15 times increase in reinfection hazard. So the UK is doing 5 times worse that South Africa. The explanation for this likely involves immune damage from the boosting campaign, as well as generally higher vaccination rate.
“Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose“ (Lancet, 2022.01.18): ”A group of German visitors who had received three doses of SARS-CoV-2 vaccines, including at least two doses of an mRNA vaccine, experienced breakthrough infections with omicron between late November and early December, 2021, while in Cape Town, South Africa. The group consisted of five White women and two White men) with an average age of 27·7 years (range 25–39) and a mean body-mass index of 22·2 kg/m2 (range 17·9–29·4), with no relevant medical history.” ALL OF THEM! “Booster doses were administered 21–37 weeks after the second vaccine doses, and breakthrough infections occurred 22–59 days thereafter. At the onset of their breakthrough infections, all individuals had high levels of viral spike protein binding antibodies, similar to levels reported 4 weeks following second vaccine doses and as expected after receipt of booster vaccine doses… The charts in the appendix show that two patients had no CD8 cells at all, including against the spike protein. And none of the patients developed CD8 cells capable of recognizing the viral membrane. The results were somewhat better for the CD4, though even those responses were nearly all below 0.1 percent, meaning that fewer than 1 out of 1,000 T-cells could recognize any of the specific viral proteins.”
“Israeli study shows 4th vaccine shot ‘not good enough’ against Omicron“ (The Times of Israel, 2022.01.17):“We see an increase in antibodies, higher than after the third dose,” she says. “However, we see many infected with Omicron who received the fourth dose. Granted, a bit less than in the control group, but still a lot of infections.”
“Mexico president says he's beaten Covid for second time“(AFP, 2022.01.17): “Mexican President Andres Manuel Lopez Obrador said Monday that he had recovered from a second bout of Covid-19. "What also helps a lot is the vaccine, getting vaccinated and not missing the booster shot," he added. Mexico's 68-year-old president, who has rarely worn a face mask during the pandemic, overcame a first bout of Covid-19 in early 2021. He has since received two doses of the AstraZeneca vaccine as well as a booster.“Who’s a moron? Rhetorical.
“Watch Australia closely“ (Alex Berenson, 2022.01.17): “The British data (which is far better and more honest than American data) make clear that throughout the fall, vaccinated people made up the vast majority of deaths from the Delta variant in the United Kingdom. That’s the truth, despite the efforts to “age-adjust” (but not comorbidity adjust) it away. Australia is now offering similar numbers. Its most populated province just reported that in the week ended Jan. 1, 12 people who died of Covid were fully vaccinated, compared to only four who were unvaccinated. …it will be very hard to hide the reality in Australia, with a nearly totally vaccinated population that has no preexisting immunity. Deporting the world’s best tennis player will do nothing to change that fact.“
“Intracranial infection cases up 60-fold since vaccines rolled out“ (Steve Kirsch, 2022.01.15): “Brain abscess is typically a bacterial infection, and often can be related to otitis/ oral cavity infection. It can also be fungal. My guess is that if indeed there is an uptick in cases, the vaccine itself is unlikely to be a direct culprit; more likely some environmental factor, or potentially masking“
“Covid infections and deaths SOAR after the first vaccine dose“ (Alex Berenson, 2022.01.13): “Stunning figures from Canada show a huge spike in cases after vaccinations; to the CDC and the media, all these deaths are occurring in the "unvaccinated."“
A new study by Kyle A. Beattie entitled “Worldwide Bayesian Causal Impact Analysis of Vaccine Administration on Deaths and Cases Associated with COVID-19: A Big Data Analysis of 145 Countries” concluded that vaccines are doing the opposite of what they were promised to do.Rather than helping us regain our freedoms, the vaccines are associated with higher rates of COVID-19 infections and higher rates of COVID-related deaths. In the US, the vaccines were associated with an increase of 38% in the number of COVID cases per million and an increase of 31% in the number of deaths per millions associated with COVID.
We included 3,442 Omicron-positive cases, 9,201 Delta-positive cases, and 471,545 test-negative controls. After 2 doses of COVID-19 vaccine, vaccine effectiveness against Delta infection declined steadily over time but recovered to 93% (95%CI, 92-94%) ≥7 days after receiving an mRNA vaccine for the third dose. In contrast, receipt of 2 doses of COVID-19 vaccines was not protective against Omicron. Vaccine effectiveness against Omicron was 37% (95%CI, 19-50%) ≥7 days after receiving an mRNA vaccine for the third dose. Conclusions Two doses of COVID-19 vaccines are unlikely to protect against infection by Omicron. A third dose provides some protection in the immediate term, but substantially less than against Delta.
But could it be that “Covid vax” unsets natural immunity and actively prevents proper multi-factor natural immunity from forming? The possibility discussed here is that the vaccinated will endlessly catch Covid, needing endless vaccine shots and having endless exposure to repeated bouts of Covid.
The study, posted on the preprint server medRxiv, August 25, 2021, concluded that those who are fully “vaccinated” against COVID-19 are in fact more susceptible to COVID variant infections than unvaccinated people. Fully vaccinated were more likely than unvaccinated persons to be infected by variants carrying mutations associated with decreased antibody neutralization (78% versus 48%), but not by those associated with increased infectivity (85% versus 77%) …
Ireland now has the highest number of patients in hospital with Covid-19 since March, despite over 91% of the population over-12 being vaccinated – the highest jab rate in the EU.
“The last 7 Public Health England / UK Health Security Agency ‘Vaccine Surveillance’ report figures on Covid-19 cases show that double vaccinated 40-79 year-olds have now lost lost 50% of their immune system capability and are consistently losing a further 5% every week (between 3.9% and 8.8%). Projections therefore suggest that 40-79 year-olds will have zero Covid / Viral defence at best, or a form of vaccine mediated acquired immunodeficiency syndrome at worst, by Christmas and all double vaccinated people over 30 will have completely lost that part of their immune system which deals with Covid-19 within the next 13 weeks.
Conclusions As this field continues to develop, clinicians and public health practitioners should consider vaccinated persons who become infected with SARS-CoV-2 to be no less infectious than unvaccinated persons. These findings are critically important, especially in congregate settings where viral transmission can lead to large outbreaks.
Results: SARS-CoV-2-naïve vaccinees had a 13.06-fold (95% CI, 8.08 to 21.11) increased risk for breakthrough infection with the Delta variant compared to those previously infected, when the first event (infection or vaccination) occurred during January and February of 2021. The increased risk was significant (P<0.001) for symptomatic disease as well. When allowing the infection to occur at any time before vaccination (from March 2020 to February 2021), evidence of waning natural immunity was demonstrated, though SARS-CoV-2 naïve vaccinees had a 5.96-fold (95% CI, 4.85 to 7.33) increased risk for breakthrough infection and a 7.13-fold (95% CI, 5.51 to 9.21) increased risk for symptomatic disease. SARS-CoV-2-naïve vaccinees were also at a greater risk for COVID-19-related-hospitalizations compared to those that were previously infected.
Conclusions: This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity.
Viral loads of breakthrough Delta variant infection cases were 251 times higher than those of cases infected with old strains detected between March-April 2020. Time from diagnosis to PCR negative was 8–33 days (median: 21). Neutralizing antibody levels after vaccination and at diagnosis of the cases were lower than those in the matched uninfected controls. There was no correlation between vaccine-induced neutralizing antibody levels and viral loads or the development of symptoms. Interpretation: Breakthrough Delta variant infections are associated with high viral loads, prolonged PCR positivity, and low levels of vaccine-induced neutralizing antibodies, explaining the transmission between the vaccinated people. Physical distancing measures remain critical to reduce SARS-CoV-2 Delta variant transmission.
Notably, in contrast to existing studies that showed lower viral load in vaccinated patients [22], initial viral load indicated by PCR Ct values was similar between vaccinated and unvaccinated patients with B.1.617.2.
…the BNT162b2 vaccine also modulated the production of inflammatory cytokines by innate immune cells upon stimulation with both specific (SARS-CoV-2) and non-specific (viral, fungal and bacterial) stimuli. The response of innate immune cells to TLR4 and TLR7/8 ligands was lower after BNT162b2 vaccination, while fungi-induced cytokine responses were stronger.
Enter your suggested resources for this topic in the comments section below.
Thanks for reading Live to Fight Another Day! Subscribe for free to receive new posts and support my work.
Booster Bust: Medical Establishment Changes Its Mind
JANUARY 14, 2022 / BRIANPECKFORD
By Vasko Kohlmayer
https://peckford42.wordpress.com/2022/01/14/booster-bust-medical-establishment-changes-its-mind/